A hand-held surgical instrument intended to be percutaneously introduced via a dedicated cannula [under external image guidance or using electrical stimulation for nerve location] to deliver radio-frequency current, in a monopolar configuration, from a system
| Company | Devices | Share |
|---|---|---|
| Avanos Medical, Inc. | 75 | 52% |
| Minta Medical Limited | 18 | 13% |
| Diros Technology Inc | 12 | 8% |
| St. Jude Medical, Inc. | 9 | 6% |
| Lccs Products Limited | 8 | 6% |
| Stratus Medical Llc | 6 | 4% |
| Medtronic Sofamor Danek, Inc. | 6 | 4% |
| Neurotherm, Inc. | 4 | 3% |
| Epimed International, Inc | 4 | 3% |
| Telea Electronic Engeenering Srl | 1 | 1% |
Company = labeler of record on GUDID. 10 companies in total; top 12 shown. Click headers to sort.
Sample of brand names as labelled; no endorsement. Ask us for the full list with company, model and UDI.
| Code | Name | Devices |
|---|---|---|
| GXI | PROBE, RADIOFREQUENCY LESION | 86 |
| GXI | Probe, radiofrequency lesion | 34 |
| GXI | Probe, Radiofrequency Lesion | 26 |
| GXD | GENERATOR, LESION, RADIOFREQUENCY | 2 |
| GEI | Electrosurgical, Cutting & Coagulation & Accessories | 1 |
Use these as the dimensions to specify in a tender line.
143 device records in commercial distribution are listed on the FDA Global Unique Device Identification Database (GUDID) under the GMDN category "Percutaneous radio-frequency ablation probe, denervation, monopolar, single-use", from 10 companies. The largest labeler is Avanos Medical, Inc. with 52% of records.
GXI (PROBE, RADIOFREQUENCY LESION), GXI (Probe, radiofrequency lesion), GXI (Probe, Radiofrequency Lesion), GXD (GENERATOR, LESION, RADIOFREQUENCY)
No. GUDID is the US register. For the UAE (MOHAP/DoH) and Saudi (SFDA/MDMA) a separate registration and a local authorised representative are required; Consulting Wallah can check the status and connect you with registered suppliers.
Add percutaneous radio-frequency ablation probe, denervation, monopolar, single-use to the RFQ basket or use the form below with quantity, specification and delivery location; the Network returns comparable quotes from verified suppliers in 2–5 working days.
Hospitals, pharmacies and distributors anywhere: tell us what you need and the Consulting Wallah Network returns comparable quotes from verified suppliers. No fee for buyers.
Source: FDA AccessGUDID (AccessGUDID full release 2 Nov 2026); counts are device records in commercial distribution grouped by GMDN preferred term; companies are labelers of record. Information only — US listing is not a registration in the UAE or GCC; verify with the regulator. © Consulting Wallah — CC BY‑NC‑ND.